123 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
64
Ending by 2030
Dec 2026
Next term end
33
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Dec 2026 · Medium confidence
Also notable
Ends no later than Jun 2031 · Medium confidence
Also notable
Ends Aug 2033 · High confidence
Inhibitors of Bruton's Tyrosine Kinase
US 7,514,444
The most cited patent in this portfolio, cited by 389 later US patents, top 1% of utility patents granted in 2009 in our data. Protection runs to 2026. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Use of Inhibitors of Bruton's Tyrosine Kinase (BTK)
US 8,754,090
Cited by 145 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Crystalline Forms of a Bruton's Tyrosine Kinase Inhibitor
US 9,540,382
Cited by 67 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Feb 4 to 25, 2027 · next Feb 4
- 4 fees due Mar 8 to 22, 2027 · next Mar 8
- 2 fees due May 5 to 19, 2027 · next May 5
- 3 fees due Sep 1 to 29, 2027 · next Sep 1
Recent changes
- 1 term has ended since Aug 16, 2026
What they patent
The 5 largest of its 33 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Inhibitors of Bruton's Tyrosine Kinase | 45 in force | to Sep 2029 |
| Use of Inhibitors of Bruton's Tyrosine Kinase (BTK) | 13 in force | to Jun 2031 |
| Crystalline Forms of a Bruton's Tyrosine Kinase Inhibitor | 12 in force | to Aug 2033 |
| Pharmaceutical Formulations of a Bruton's Tyrosine Kinase Inhibitor | 5 in force | to Mar 2036 |
| Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | 4 in force | to Jan 2030 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,514,444 | Inhibitors of Bruton's Tyrosine Kinase In force · Medium confidence | In force | Medium confidence | |
| US 7,960,396 | Inhibitors of Bruton's Tyrosine Kinase In force · Medium confidence | In force | Medium confidence | |
| US 8,158,786 | Inhibitors of Bruton's Tyrosine Kinase In force · Medium confidence | In force | Medium confidence | |
| US 8,232,280 | Inhibitors of Bruton's Tyrosine Kinase In force · Low confidence | In force | Low confidence | |
| US 8,236,812 | Inhibitors of Bruton's Tyrosine Kinase In force · High confidence | In force | High confidence | |
| US 8,399,470 | Inhibitors of Bruton's Tyrosine Kinase In force · Low confidence | In force | Low confidence | |
| US 8,476,284 | Inhibitors of Bruton's Tyrosine Kinase In force · Low confidence | In force | Low confidence | |
| US 8,497,277 | Inhibitors of Bruton's Tyrosine Kinase In force · Low confidence | In force | Low confidence | |
| US 8,501,751 | Inhibitors of Bruton's Tyrosine Kinase In force · Medium confidence | In force | Medium confidence | |
| US 8,552,010 | Inhibitors of Bruton's Tyrosine Kinase In force · High confidence | In force | High confidence |
Also on record, not counted in the 123: 1 patent in force now held by others · 39 patents ended · 5 applications pending · 149 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.